Lv12
30 积分 2024-09-23 加入
Long-term outcomes of IgA nephropathy in China
13小时前
已完结
Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial
2天前
已完结
Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial
2天前
已完结
Primary Hyperoxaluria
10个月前
已完结
皖公网安备34019202002308
